Teva wins biosimilar approval of Amgen's Xgeva
The US FDA approved Teva's Degevma, a biosimilar to Amgen's Xgeva, for preventing bone damage in cancer patients. Approval was based on data showing similar efficacy and safety. Teva also received approval for Ponlimsi, a biosimilar to Amgen's Prolia, in March. Amgen reported $763M in Xgeva revenue for H1 2026.
How this was made
The 30-second read
Why it matters
The approval expands Teva's oncology pipeline and could capture market share from Amgen's Xgeva.
Market read
Regulatory clearance for a major biosimilar is a high‑impact catalyst for the issuer and the broader biosimilar market.
What to watch
Potential reimbursement challenges and competition from other biosimilars.
Background
FDA approval of a biosimilar is a regulatory milestone that can materially affect the issuer's valuation.
Ticker impact
US FDA approved Teva's biosimilar Degevma to Amgen's Xgeva, expanding its oncology portfolio.
likely upside as the market prices in the biosimilar approval
FDA clearance removes regulatory uncertainty and opens a sizable market previously dominated by Amgen.
Market effects
Strengthens the biosimilar segment within the pharma sector, pressuring peers.
Positive for US biotech and generic drug manufacturers.
May influence global pricing dynamics for denosumab products.
Counterpoint
If pricing pressure forces Amgen to cut Xgeva prices, Teva's upside could be limited.
Key entities
- companyTeva Pharmaceutical Industries
US-listed pharmaceutical company receiving FDA approval.
- companyAmgen
Original developer of Xgeva, referenced as the reference product.
